

FDA-APPROVED OVARIAN CANCER TREATMENTS

Generic	Brand	Strength	Form	Usual Dose
ALKYLATING AGENT				
altretamine	Hexalen	50mg	caps	260mg/m ² daily in four divided doses for either 14 or 21 consecutive days in a 28-day cycle
carboplatin	—	10mg/mL	soln for IV infusion	<i>Advanced ovarian cancer (previously untreated):</i> 300mg/m ² on Day 1 every 4wks for 6 cycles <i>Recurrent ovarian cancer:</i> 360mg/m ² on Day 1 every 4wks
cisplatin	—	1mg/mL	soln for IV infusion after dilution	100mg/m ² once every 4wks
cyclophosphamide	—	25mg, 50mg	tabs	1–5mg/kg/day
		500mg, 1g, 2g	pwd for inj after reconstitution	40–50mg/kg in divided doses over 2–5 days or 10–15mg/kg every 7–10 days or 3–5mg/kg twice weekly
melphalan	Alkeran	2mg	scored tabs	0.2mg/kg/day for 5 days; repeat every 4–5wks
thiotepa	—	15mg	pwd for IV, intravesical, or intracavitary administration after reconstitution	0.3–0.4mg/kg IV once every 1–4wks
ANTIBIOTICS (CYTOTOXIC)				
doxorubicin	—	10mg, 20mg, 50mg	pwd for IV inj after reconstitution	<i>Monotherapy:</i> 60–75mg/m ² every 21 days <i>Combination therapy:</i> 40–60mg/m ² every 21 to 28 days
		2mg/mL	soln for IV inj	
doxorubicin (liposomal)	Doxil	2mg/mL	dispersion for IV infusion after dilution	50mg/m ² once every 4wks
ANTIMETABOLITE				
gemcitabine	Gemzar	200mg, 1g	pwd for IV infusion after reconstitution	1000mg/m ² on Days 1 and 8 of each 21-day cycle; give with carboplatin administered on Day 1 after gemcitabine
ANTIMICROTUBULE AGENTS				
paclitaxel	Taxol	6mg/mL	soln for IV administration after dilution	<i>Previously untreated ovarian cancer:</i> 175mg/m ² over 3hrs or 135mg/m ² over 24hrs; repeat every 3wks <i>Previously treated ovarian cancer:</i> 135mg/m ² or 175mg/m ² over 3hrs every 3wks
POLY (ADP-RIBOSE) POLYMERASE INHIBITOR				
olaparib	Lynparza*	50mg	caps	400mg twice daily until disease progression or unacceptable toxicity; max 800mg daily
		100mg, 150mg	tabs	300mg twice daily until disease progression or unacceptable toxicity; max 600mg daily
rucaparib	Rubraca*	200mg, 250mg, 300mg	tabs	600mg twice daily until disease progression or unacceptable toxicity
TOPOISOMERASE INHIBITOR				
topotecan	Hycamtin	4mg	pwd for IV infusion after reconstitution and dilution	1.5mg/m ² daily for 5 consecutive days starting on Day 1 of a 21-day cycle

NOTES

*For patients with deleterious BRCA-mutated (as detected by an FDA-approved test) advanced ovarian cancer.

Not an inclusive list of medications and/or doses. Please see drug monograph at www.eMPR.com and/or contact company for full drug labeling.